Xencor (XNCR) to Release Quarterly Earnings on Thursday

Xencor (NASDAQ:XNCR) is expected to issue its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.64) per share for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Wednesday, February 25, 2026 at 9:30 AM ET.

Xencor Stock Performance

Shares of Xencor stock opened at $11.34 on Thursday. The stock has a market capitalization of $809.79 million, a PE ratio of -6.41 and a beta of 0.98. Xencor has a 52 week low of $6.92 and a 52 week high of $18.69. The stock has a 50 day moving average price of $13.74 and a two-hundred day moving average price of $12.59.

Insider Transactions at Xencor

In related news, CEO Bassil I. Dahiyat sold 114,377 shares of the stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $15.71, for a total transaction of $1,796,862.67. Following the completion of the sale, the chief executive officer directly owned 466,635 shares of the company’s stock, valued at approximately $7,330,835.85. This trade represents a 19.69% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP John R. Desjarlais sold 73,367 shares of Xencor stock in a transaction on Friday, December 19th. The stock was sold at an average price of $15.72, for a total value of $1,153,329.24. Following the sale, the vice president owned 236,574 shares in the company, valued at $3,718,943.28. This trade represents a 23.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 4.76% of the company’s stock.

Hedge Funds Weigh In On Xencor

Several institutional investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC boosted its stake in Xencor by 118.4% in the second quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 3,018 shares during the last quarter. E Fund Management Co. Ltd. purchased a new position in Xencor in the second quarter valued at approximately $79,000. iSAM Funds UK Ltd purchased a new stake in Xencor in the second quarter worth $122,000. Prelude Capital Management LLC bought a new stake in shares of Xencor in the third quarter valued at $139,000. Finally, Creative Planning lifted its position in shares of Xencor by 25.3% during the 2nd quarter. Creative Planning now owns 18,130 shares of the biopharmaceutical company’s stock valued at $143,000 after buying an additional 3,661 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on XNCR. Weiss Ratings restated a “sell (d-)” rating on shares of Xencor in a research note on Monday, December 29th. JPMorgan Chase & Co. reduced their price objective on shares of Xencor from $20.00 to $18.00 and set an “overweight” rating for the company in a report on Thursday, November 6th. Royal Bank Of Canada upped their target price on shares of Xencor from $18.00 to $19.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. Barclays raised their price target on shares of Xencor from $23.00 to $26.00 and gave the company an “overweight” rating in a research report on Wednesday, December 17th. Finally, Truist Financial initiated coverage on Xencor in a report on Monday, November 24th. They set a “buy” rating and a $29.00 price objective for the company. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Xencor currently has an average rating of “Moderate Buy” and a consensus target price of $24.88.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.